Ebola outbreaks: A stress test of the preparedness of medicines regulatory systems for public health crises.


Journal

Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391

Informations de publication

Date de publication:
11 2021
Historique:
received: 18 04 2021
revised: 17 05 2021
accepted: 14 06 2021
pubmed: 1 8 2021
medline: 17 3 2022
entrez: 31 7 2021
Statut: ppublish

Résumé

In a globalized world, infectious diseases of international concern are inevitable. When they (re-)emerge, the regulatory system works towards mitigating their impact. Ebola outbreaks marked a turning point in regulatory preparedness and efforts led to the accelerated development of therapeutic agents, in a catastrophic environment. However, only one clinical trial determined a vaccine's efficacy. Key lessons were considered and applied thereafter. The collaborative work resulted in the approval of the first therapeutic options against Ebola, a milestone in public health preparedness. The response demonstrated the successful implementation of regulatory mechanisms fostering development, early access and assessment of therapeutic agents, and the flexibility to embrace innovative regulatory solutions. The current system is robust to address health crises and protect global health.

Identifiants

pubmed: 34332099
pii: S1359-6446(21)00329-9
doi: 10.1016/j.drudis.2021.06.019
pii:
doi:

Substances chimiques

Antiviral Agents 0
Ebola Vaccines 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2608-2618

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Auteurs

Rafael Amaral (R)

Faculdade de Farmácia, Universidade de Lisboa, 1649-003 Lisbon, Portugal.

Carla Torre (C)

Faculdade de Farmácia, Universidade de Lisboa, 1649-003 Lisbon, Portugal; Laboratory of Systems Integration Pharmacology, Clinical & Regulatory Science - Research Institute for Medicines (iMED.ULisboa), 1649-003 Lisbon, Portugal.

João Rocha (J)

Faculdade de Farmácia, Universidade de Lisboa, 1649-003 Lisbon, Portugal; Laboratory of Systems Integration Pharmacology, Clinical & Regulatory Science - Research Institute for Medicines (iMED.ULisboa), 1649-003 Lisbon, Portugal.

Bruno Sepodes (B)

Faculdade de Farmácia, Universidade de Lisboa, 1649-003 Lisbon, Portugal; Laboratory of Systems Integration Pharmacology, Clinical & Regulatory Science - Research Institute for Medicines (iMED.ULisboa), 1649-003 Lisbon, Portugal. Electronic address: bsepodes@ff.ulisboa.pt.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH